Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis
Abstract Background Toxoplasma gondii is an obligate intracellular parasite that can infect almost all warm-blooded animals, avian species and humans. Toxoplasmosis is asymptomatic in healthy individuals, whereas it may lead to death in immune suppressed or deficient patients. A vaccine against T. g...
Main Authors: | Esra Atalay Şahar, Hüseyin Can, Sultan Gülçe İz, Aysu Değirmenci Döşkaya, Mina Kalantari-Dehaghi, Remziye Deveci, Adnan Yüksel Gürüz, Mert Döşkaya |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12879-020-05220-2 |
Similar Items
-
Using Montanide™ ISA 50 V2 as adjuvant for the formulation of the anti-tick Gavac® vaccine
by: Carlos Perez Heredia, et al.
Published: (2017-12-01) -
Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine
by: Ehab El-Sayed Ibrahim, et al.
Published: (2015-10-01) -
LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of leptospirosis
by: Vivek P. Varma, et al.
Published: (2022-10-01) -
Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis
by: Tuğba Karakavuk, et al.
Published: (2022-12-01) -
Immunomodulating Efficacy Of Different Adjuvants In Formulation Of Foot And Mouth Disease Vaccine Relative To Its Immunogenicity
by: El-Sayed, E. I., et al.
Published: (2020-07-01)